Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
FNMFO FNMFO 096770 KDDIF Airlines Conglomerates Realty Macroaxis Picks 
United States  USA  |  Create Portfolios


Processing
Collecting data for SOMX

Somaxon quote and profile

 
 Companies |  Insiders  | Dashboard  
     
3.0
  
STOCK
0.00  No Change   0.00%  
May 19 2013 

Diversification Suggestion

Use Somaxon to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Check current 30 days Somaxon correlation with market (S&P 500)
1 Month Beta 0.0  
Unless we do not have data at the moment the returns on S&P 500 and Somaxon are completely uncorrelated
Somaxon Pharmaceuticals Inc not significant BetaSomaxon Pharmaceuticals Beta Legend
SOMX United States Nasdaq
Somaxon Pharmaceuticals Inc
http://www.somaxon.com
Contact Number: 858. 876. 6500
Traded on Nasdaq Capital Markets
    
Current Valuation11.85 M
Shares Outstanding7.19 M
Number of Shares Shorted279.61 K
Revenue12.14 M
 United States Russel   1.11 % Macroaxis: change 1.11 Moved Up  
 
 United States SP 500   1.03 % Macroaxis: change 1.03 Moved Up  
 
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States NYSE   0.92 % Macroaxis: 0.92 Moved Up  
 
 thisGreen SOMX SOMX agains markets  0.00 % No Change  
Compare to Competition Get Alpha   Get Advice

Somaxon Leadership

Richard Pascoe CEO and President and Director
David Hale Co-Founder and Executive Chairman
Tran Nguyen CFO, Senior Vice President, MBA
Tran MBA CFO, Principal Accounting Officer and Sr. VP

Somaxon Summary

Somaxon Pharmaceuticals Inc [SOMX] is traded on Nasdaq Capital Markets in USA. It is located in Somaxon Pharmaceuticals, Inc.San Diego, CA and employs 36 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 20.28 M. Somaxon Pharmaceuticals Inc has 7.19 M outstanding shares of which 279.61 K shares are at this time shorted by private and institutional investors with about 4.4 trading days to cover.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the inlicensing, development, and commercialization of proprietary branded solutions and latestage product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. more
Follow Somaxon with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Somaxon to your reader
 

Somaxon Research Report

Somaxon vs. Federal

Correlation analysis and fundamentals comparison between Somaxon Pharmaceuticals and Federal National Mor

Somaxon Executives

Tran MBA CFO, Principal Accounting Officer and Sr. VP

Somaxon Directors

Terrell Cobb Director
Erle Mast Independent Director
Michael Eagle Director, MBA
Faheem Hasnain Independent Director
Kurt Emster Independent Director

Somaxon Management

Brian Dorsey Sr. VP of Technical Operations

Somaxon Fundamentals

Total Asset vs One Year Low
Current Liabilities vs Price to Earnings To Growth
Total Asset vs Cash and Equivalents
Price to Sales vs Price to Earnings To Growth

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium